Mersana Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have filed a Schedule 13G amendment indicating they no longer beneficially own any shares of Mersana Therapeutics, Inc. common stock following a merger.
683 Capital Management, LLC and its affiliates disclosed a 7.03% beneficial ownership stake in Mersana Therapeutics, Inc. as of December 31, 2025.
The Vanguard Group has filed an amended Schedule 13G, disclosing a 4.20% beneficial ownership in Mersana Therapeutics Inc. common stock, indicating a reduction below the 5% threshold.
Nextech Crossover I GP S.a. r.l. and related entities have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Mersana Therapeutics, Inc. common stock.
683 Capital Management, LLC and its affiliates have reported a 5.47% beneficial ownership stake in Mersana Therapeutics, Inc. common stock.
Schonfeld Strategic Advisors LLC has reported a 5.48% beneficial ownership stake in Mersana Therapeutics, Inc., holding 273,579 shares of common stock.
Schonfeld Strategic Advisors LLC has disclosed an increased passive ownership stake of 4.55% in Mersana Therapeutics, Inc.
SCHEDULE 13G/A: BlackRock Reports Reduced 3.0% Stake in Mersana Therapeutics
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, reporting beneficial ownership of 3.0% of Mersana Therapeutics Inc.'s common stock as of June 30, 2025.
SCHEDULE 13G/A: Venrock Healthcare Capital Partners Group Maintains 2.9% Passive Stake in Mersana Therapeutics
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, reporting a collective passive beneficial ownership of 2.9% of Mersana Therapeutics, Inc.'s common stock as of March 31, 2025.
Schonfeld Strategic Advisors LLC has reported a passive beneficial ownership of 6.11% of Mersana Therapeutics, Inc.'s common stock as of March 31, 2025.
SCHEDULE 13G/A: EcoR1 Capital Divests Entire Stake in Mersana Therapeutics, Filing Shows 0% Beneficial Ownership
Investment firm EcoR1 Capital, LLC and its affiliates have reported a 0% beneficial ownership stake in Mersana Therapeutics, Inc., indicating a complete divestment or reduction below the reporting threshold.
The Vanguard Group has filed an amended Schedule 13G, reporting a 6.72% beneficial ownership stake in Mersana Therapeutics Inc. as of March 31, 2025.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% passive beneficial ownership stake in Mersana Therapeutics Inc. as of March 31, 2025.
Venrock Healthcare Capital Partners and affiliated entities have filed an amended Schedule 13G, reaffirming their collective beneficial ownership of 8.3% of Mersana Therapeutics, Inc.'s common stock as of December 31, 2024.
BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a passive beneficial ownership of 8.0% in Mersana Therapeutics Inc. as of December 31, 2024.